No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
127 |
4. Check minimum number of eventsNone |
127 |
5. Include endpointsNone |
127 |
6. Filter based on genotype QC (FinnGen only) |
124 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Neuroendocrine tumor and carcinoma of rectum
based on the number of shared cases.
Similar with more cases:
- Colorectal neuroendocrine tumor and carcinoma
- Colorectal cancer
- Malignant neoplasm of digestive organs
- Solid cancers, helper endpoint
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 124 | 70 | 54 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 56.85 | 53.92 | 60.66 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 127
- Matched controls
- 1270
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8240/3-C20.9
ICD-O-3
Neuroendocrine tumor, NOS, of rectum, NOS
+∞
141.4
108
*
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
35.3
91.2
71
44
D12.8
ICD-10 Finland
Benign neoplasm: Rectum
33.4
70.8
51
25
C20.99
ICD-10 Finland
Malignant tumor of the rectum other or unspecified histology
+∞
28.2
26
*
UJF32
NOMESCO Finland
Coloscopy
5.6
20.8
64
196
130
Kela drug reimbursment
Malignant tumour
+∞
19.2
18
*
UJF30
NOMESCO Finland
Ileoscopy through colon
7.0
18.2
33
61
D37.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Rectum
49.7
17.9
21
5
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
+∞
16.0
15
*
C20.90
ICD-10 Finland
Malignant tumor of the rectum without histology
+∞
13.8
13
*
K62.1
ICD-10 Finland
Rectal polyp
52.0
12.1
14
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
11.6
11
*
E34.0
ICD-10 Finland
Carcinoid syndrome
+∞
11.6
11
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
11.6
11
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
11.6
11
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.7
11.6
32
85
D12.6
ICD-10 Finland
Benign neoplasm: Colon, unspecified
6.0
11.3
22
43
H02AB02
ATC
dexamethasone; systemic
31.1
11.0
14
5
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
10.6
10
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.3
9.8
63
294
C20
ICD-10 Finland
Malignant neoplasm of rectum
+∞
9.5
9
*
L01BC06
ATC
capecitabine; oral
+∞
9.5
9
*
L01AX03
ATC
temozolomide; systemic
+∞
9.5
9
*
8249/3-C20.9
ICD-O-3
Neuroendocrine tumor, grade 2 of rectum, NOS
+∞
8.4
8
*
JFA15
NOMESCO Finland
Endoscopic polypectomy in colon
5.0
8.2
19
43
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.4
7
*
H01CB02
ATC
octreotide; parenteral
+∞
7.4
7
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
13.2
6.7
11
9
JN4BD
NOMESCO Finland
Extensive body CT
6.2
6.6
17
31
C18.90
ICD-10 Finland
Malignant tumor in unspecified location in the colon without histology
+∞
6.3
6
*
JN7AQ
NOMESCO Finland
Somatostatin receptor SPET med low dose CT
+∞
6.3
6
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
26
59
5.28
11.34
3.8
1.4
25.15
2.77
ug/l
0.49
21
43
77
399
3.36
10.17
5.7
3.4
35.57
35.87
g/l
0.18
71
368
75
450
2.63
6.57
18.3
11.8
1.30
1.28
inr
0.07
25
130
54
306
2.33
5.01
5.5
2.0
2.36
2.35
mmol/l
0.42
49
255
16
48
3.67
4.79
4.9
7.5
24.51
25.23
mmol/l
0.35
16
48
57
340
2.23
4.60
2.6
2.8
—
—
—
0
0
45
268
2.05
3.47
2.5
2.7
0.19
0.45
e6/l
1.12
30
197
99
788
2.16
3.26
4.0
4.0
14.25
11.60
mm/h
0.74
92
714
75
548
1.90
3.08
12.2
5.4
4.35
4.20
e9/l
0.21
67
470
18
79
2.49
2.83
3.8
3.1
—
—
—
0
0
22
108
2.25
2.72
4.4
5.8
103.91
104.43
mmol/l
0.31
22
108
6
11
5.66
2.57
1.2
1.5
2.73
339.11
u/ml
—
6
11
115
1007
2.50
2.46
17.4
10.1
80.27
80.01
ml/min/173m2
0.05
101
787
63
459
1.74
2.42
7.5
5.2
1.22
1.22
mmol/l
0.13
52
399
13
54
2.57
2.28
1.8
1.4
—
—
—
0
0
65
484
1.70
2.27
3.6
4.3
0.00
0.00
estimate
-0.00
13
89
33
204
1.83
2.18
2.2
1.8
—
—
—
0
0
117
1051
2.44
2.02
17.5
11.1
17.87
21.71
mg/l
0.89
96
780
63
480
1.62
1.92
3.0
3.2
0.00
0.01
estimate
0.50
13
97
8
28
2.98
1.90
1.3
1.3
—
—
—
0
0
64
492
1.61
1.86
2.9
3.2
0.00
0.00
estimate
-0.00
12
84
38
256
1.69
1.86
3.6
3.5
0.00
0.00
estimate
-0.00
13
86
56
423
1.58
1.72
2.4
2.1
—
—
—
0
0
49
377
1.49
1.32
3.3
3.2
—
—
—
0
0
8
38
2.18
1.21
3.1
1.5
—
—
—
0
0
51
402
1.45
1.19
3.6
2.2
73.87
77.89
nmol/l
0.48
46
351
41
312
1.46
1.14
4.0
2.7
813.10
1114.04
ng/l
0.46
29
262
22
146
1.61
1.13
2.8
2.6
0.79
2.96
e6/l
1.16
12
66
46
359
1.44
1.13
3.6
3.9
2.82
10.15
mg/mmol
2.31
27
226
29
206
1.53
1.12
1.9
1.8
470.65
442.25
pmol/l
0.31
23
162
5
21
2.44
1.10
2.0
1.1
—
—
—
0
0
23
157
1.57
1.05
2.7
2.4
0.45
1.13
e6/l
1.61
13
77
26
183
1.53
1.05
1.8
1.6
1384.05
1254.94
nmol/l
0.25
19
135
9
49
1.90
1.01
1.6
1.4
—
—
—
0
0
0
31
0.00
0.98
0.0
1.3
—
11.99
—
0
9
6
27
2.28
0.95
1.2
1.2
—
—
—
0
0
122
1170
2.08
0.81
26.2
16.3
40.43
40.77
%
0.39
114
1081
9
54
1.72
0.76
6.7
8.6
0.99
1.57
%
—
9
54
51
428
1.32
0.76
2.4
1.9
86.40
97.04
pmol/l
1.00
30
198
7
41
1.75
0.71
4.0
1.1
2.76
2.86
g/l
—
7
36
7
43
1.66
0.68
4.0
1.1
3.33
3.71
g/l
—
7
38
7
43
1.66
0.68
4.0
1.1
6.87
7.62
g/l
—
7
38
7
43
1.66
0.68
4.0
1.1
—
—
—
0
0
28
221
1.34
0.63
1.4
1.6
1.75
1.11
mg/l
0.45
21
170
21
159
1.38
0.60
1.5
1.4
—
—
—
0
0
8
53
1.54
0.59
7.4
8.7
0.76
0.73
%
—
8
53
0
23
0.00
0.59
0.0
1.3
—
67.91
—
0
23
6
35
1.75
0.58
3.8
1.1
40.18
38.58
g/l
—
6
30
6
36
1.70
0.57
1.0
1.4
—
—
—
0
0
6
38
1.61
0.55
3.8
1.1
9.63
10.34
g/l
—
6
33
14
189
0.71
0.53
1.4
1.3
1.20
11.33
u/ml
—
5
68
104
988
1.29
0.47
5.3
4.4
1.94
1.93
mu/l
0.02
96
897
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
0.87
—
0
7
5
35
1.45
0.40
1.4
1.2
—
—
—
0
0
5
35
1.45
0.40
1.4
1.2
—
—
—
0
0
20
162
1.28
0.38
1.4
1.4
—
—
—
0
0
111
1070
1.30
0.38
5.1
4.4
6.17
6.00
mmol/l
0.68
101
979
17
135
1.30
0.37
7.1
5.8
—
—
—
0
0
12
90
1.37
0.37
5.5
7.1
113.00
123.26
g/l
1.18
12
90
6
43
1.41
0.35
2.3
2.7
24.02
25.30
mmol/l
—
6
43
25
290
0.83
0.31
4.2
3.4
26.32
25.08
%
0.11
15
122
7
55
1.29
0.30
1.9
1.4
—
—
—
0
0
63
585
1.15
0.30
2.5
2.8
—
—
—
0
0
75
706
1.15
0.29
3.4
3.0
59.20
47.37
u/l
0.42
70
665
110
1068
1.22
0.27
4.4
4.6
1.43
1.50
mmol/l
0.85
100
986
45
413
1.14
0.24
4.5
3.4
22.29
40.09
ng/l
1.29
35
284
26
229
1.17
0.24
1.3
1.3
0.49
0.82
u/ml
—
7
54
0
11
0.00
0.21
0.0
1.4
—
169.07
—
0
11
0
11
0.00
0.21
0.0
2.6
—
13.61
—
0
11
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
2.40
—
0
5
0
14
0.00
0.20
0.0
1.3
—
5.50
—
0
8
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
110
1076
1.17
0.18
4.6
4.6
4.52
4.69
mmol/l
0.93
101
997
16
139
1.17
0.17
1.4
1.7
—
—
—
0
0
6
75
0.79
0.16
1.5
2.5
—
—
—
0
0
82
798
1.08
0.11
4.8
3.6
14.98
14.74
pmol/l
0.34
76
719
7
67
1.05
0.08
1.1
2.4
—
—
—
0
0
104
1026
1.08
0.07
6.7
5.8
41.18
40.14
mmol/mol
0.47
96
961
104
1028
1.06
0.05
4.1
4.1
1.39
1.29
mmol/l
0.75
95
946
111
1099
1.08
0.05
5.1
5.2
2.59
2.76
mmol/l
1.09
102
1010
31
300
1.04
0.03
1.5
1.6
1.43
1.34
mmol/l
0.23
26
252
10
98
1.02
0.00
1.3
1.7
—
—
—
0
0
10
98
1.02
0.00
1.3
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
30.83
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_RECTUM_NEUROENDOCRINE – Neuroendocrine tumor and carcinoma of rectum
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).